scientifica sessions.
Hosted by Tabari Baker, CEO of kronos scientifica, scientifica sessions features unscripted conversations with the executives, innovators, and visionaries shaping the future of biotech, medtech, pharma, and healthtech. Each episode dives into the realities of leadership in a rapidly evolving industry: scaling medical affairs and commercial teams, building investor confidence, navigating regulatory shifts, unlocking digital health and AI, and driving commercialization strategies that matter. Guests share candid stories from the boardroom to the clinic—what worked, what didn’t, and what’s next. If you’re a CEO, CMO, commercial leader, investor, or startup founder, scientifica sessions gives you insider access to the lessons, strategies, and perspectives that don’t show up in press releases or pitch decks.
info_outline
The Dark Side of Data: Power, Privacy, and the Pursuit of Precision
11/15/2025
The Dark Side of Data: Power, Privacy, and the Pursuit of Precision
Episode Description In this episode of scientifica sessions, we take an unfiltered look at the complex relationship between innovation, privacy, and power in healthcare data with Ardy Arianpour, CEO and Co-Founder of SEQSTER. The life sciences industry is overflowing with data—EHRs, genomic profiles, claims data, wearables, and AI-driven predictions—but more data doesn’t always mean better decisions. Together with host Tabari Baker, Ardy explores what happens when the pursuit of precision meets the realities of fragmentation, bias, and inequity. They unpack the hidden challenges behind the data revolution: the illusion of completeness in large datasets, the ethical tension between personalization and surveillance, and the growing misalignment between global privacy frameworks and real-world innovation. From AI model bias to the regulatory maze that stifles collaboration, this conversation challenges industry leaders to rethink how data is collected, governed, and used responsibly across research and patient engagement. Whether you’re leading Medical Affairs, building digital health infrastructure, or shaping data strategy in biotech or pharma, this episode offers a grounded perspective on how to move toward a transparent, patient-centric data economy—one that values trust as much as technology. What We Covered Data Abundance, Insight Scarcity Why more data doesn’t always yield better understanding How fragmented datasets create false completeness The strain on R&D, Medical Affairs, RWE, and HEOR teams The Ethics of Data Ownership Who really owns patient data: the patient, provider, or payer? Why consent frameworks fail in real-time and longitudinal data use The fine line between personalization and surveillance Data Quality and Bias in AI Models How bias propagates through clinical AI systems The challenge of verifying data integrity across multiple sources Why Medical Affairs must serve as the ethical interpreter of AI insights The Regulatory Maze Global misalignment between FDA, EMA, and HIPAA-like frameworks How privacy laws (GDPR, CCPA, 21 CFR Part 11) impede collaboration Emerging models for responsible cross-border data exchange Toward a Responsible Data Future What a transparent, patient-centric data economy could look like How collaborations are setting new ethical standards The growing role of Medical Affairs in bridging innovation and integrity Guest Bio Ardy Arianpour is the CEO and Co-Founder of SEQSTER, the pioneering health-tech company putting patients at the center of their health data. A visionary executive with more than 20 years of experience in life sciences, pharma, and digital health, Ardy has dedicated his career to breaking barriers in how health data is accessed, shared, and used to improve outcomes. Before founding SEQSTER in 2016, he helped launch multiple groundbreaking genetic tests as Chief Commercial Officer at Pathway Genomics and Senior Vice President at Ambry Genetics, which sold to Konica in 2017 for $1 billion. A key contributor to the landmark 2013 Supreme Court decision ending gene patenting, Ardy helped expand national access to BRCA testing. He has been recognized as a PharmaVoice 100 Inspiring Leader (2023 & 2024), a Top 40 Healthcare Transformer, and one of Insights Success’ Top 10 Pioneers Redefining Healthcare. Ardy serves as Faculty at NextMed.Health, Judge for the Top Tech Awards, and an Advisor to UCSD’s Digital Health Board, Inside Precision Medicine, and the Fleet Science Center. Connect with Ardy 📧 🌐 🔗 If You Liked This Episode… If this conversation made you rethink how your organization handles data, governance, and trust, share it with your team—and subscribe to Scientifica Sessions. We bring you unscripted conversations with the people defining the future of biotech, pharma, and medtech. 📩 Connect with the show at . At scientifica sessions, we love our music! Here's are the original tracks used: 1. 00:08:32 - Where Are We Going? 2. 00:15:15 - Bring the Hustle 3. 00:20:45 - Crystalize 4. 00:29:45 - Soyuz Space Guitar 5. 00:39:10 - Lore Episode recorded on October 22, 2025. All information shared is current as of the recording date.
/episode/index/show/4bf1c28b-29db-4d52-81c6-5158929c0248/id/38808410
info_outline
From Wearables to Real-World Evidence: Drew Schiller on the Future of Life Sciences
09/02/2025
From Wearables to Real-World Evidence: Drew Schiller on the Future of Life Sciences
Episode Description In this episode of scientifica sessions, we dive deep into the transformative world of real-world evidence (RWE) and patient-generated health data (PGHD) with Drew Schiller, CEO of Validic. As life sciences companies increasingly recognize the value of data from wearables, remote monitoring devices, and connected health platforms, Drew shares practical insights on how even resource-constrained startups and emerging biotechs can harness this data to drive medical strategy and support value-based care initiatives. We explore the evolving regulatory landscape, including the FDA's recent action on Whoop's Blood Pressure Insights feature, and discuss how companies can navigate the fine line between wellness tools and medical devices. Drew provides actionable guidance for life sciences leaders, MSLs, and clinical strategists looking to integrate patient-generated data into their evidence strategies without breaking the bank or crossing regulatory boundaries. Whether you're at a lean startup or a commercial-stage company, this episode offers concrete strategies for leveraging the data-rich world we live in to improve patient outcomes and build compelling value stories. What We Covered Defining Real-World Evidence in Early-Stage Settings Understanding RWE in the context of resource-limited companies Where patient-generated health data fits in the evidence ecosystem Common misconceptions about collecting and using real-world data Practical Use Cases for Life Sciences Most accessible types of patient-generated data for lean teams How companies are using PGHD/RWE to inform medical strategy Opportunities for hyper-personalization of therapies Balancing privacy, interoperability, and evidence generation PGHD's Role in Pharma Strategy & Value-Based Care How patient-generated data enables value-based care models The shift from volume to value and its impact on external data sources Real-world examples of remote monitoring supporting value-based initiatives Why Medical Affairs and Commercial teams should prioritize PGHD Regulatory Considerations: Learning from the FDA's Whoop Warning Implications of FDA's stance on patient-generated blood pressure data Navigating wearable integration without crossing medical device boundaries Ensuring compliance while harnessing continuous health data Future partnerships between life sciences and digital health platforms Strategic Advice for Data-Driven Evidence Guidance for biotech CMOs and VPs of Medical Affairs The future of wearable/app data in value dossiers and HEOR submissions Recommended platforms and partners for startups vs. larger companies Guest Bio Drew Schiller is the co-founder and CEO of Validic, a leading digital health platform connecting personal health data from wearables, in-home devices, and mobile apps to healthcare companies, systems, and providers. Under his leadership, Validic has powered scalable remote patient monitoring and real-world data strategies for some of the largest healthcare organizations in the world. A recognized voice in connected health and digital transformation, Drew serves on the board of the Consumer Technology Association's Health Division, in addition to serving on various industry boards. Drew brings a product-driven perspective to healthcare innovation, helping organizations design and implement real-world evidence strategies that center on patient-generated health data. He is passionate about empowering companies with real-time, high-resolution insights to improve patient outcomes—especially in lean, early-stage settings where traditional data infrastructure may be limited. Connect with Drew: Website: LinkedIn: Email: If you're leading a startup or emerging biotech and wondering how to tap into real-world patient data without massive infrastructure investment, visit . Validic helps organizations of all sizes connect wearable, app, and in-home health data into evidence strategies that actually work. Start thinking differently about how you engage with patients, evidence, and digital health. If this conversation sparked new ideas or made you rethink how you align discovery with downstream strategy, subscribe to scientifica sessions. We bring you the leaders shaping what's next in biotech, medtech, and pharma. Connect with us at . scientifica sessions is produced by kronos scientifica, exploring the intersection of innovation, evidence, and strategy in life sciences. At scientifica sessions, we love our music! Here's are the original tracks used: 1. 00:07:42 - Whirl 2. 00:15:30 - A Night in November 3. 00:21:06 - Night Walk 4. 00:26:28 - Rico Clave 5. 00:38:30 - Bubble Trouble 6. 00:47:37 - UP! 7. 00:56:22 - A Different Cat Episode recorded on July 21, 2025. All information shared is current as of the recording date.
/episode/index/show/4bf1c28b-29db-4d52-81c6-5158929c0248/id/38051605
info_outline
scientifica sessions: Welcome to the Conversation
09/01/2025
scientifica sessions: Welcome to the Conversation
In this inaugural episode, host Tabari Baker, Founder & CEO of kronos scientifica, introduces Scientifica Sessions—a new podcast at the intersection of science, strategy, and commercialization. With over 15 years of leadership experience in medical affairs, clinical development, and biotech commercialization, Tabari has worked with companies navigating late-stage trials, preparing for launch, and building medical organizations ready for global growth. He’s seen firsthand that great science alone isn’t enough—it takes evidence, strategy, and authentic engagement to bring innovation from concept to clinic. This episode sets the stage for what’s to come: candid conversations with scientists, biotech founders, investors, patient advocates, and industry leaders who are shaping the future of medicine. Expect clear insights, practical lessons, and stories that go beyond the headlines. Whether you’re an executive, a founder, or simply curious about how science becomes solutions, this is your invitation to join the conversation. Subscribe now to hear future episodes of scientifica sessions, and discover what it really takes to turn ideas into impact. Like what you heard? Check out our producers, .
/episode/index/show/4bf1c28b-29db-4d52-81c6-5158929c0248/id/38051285
info_outline
Generative Chemogenomics & the Future of Drug Discovery: Inside AI‑Driven R&D with Tom Neyarapally
09/01/2025
Generative Chemogenomics & the Future of Drug Discovery: Inside AI‑Driven R&D with Tom Neyarapally
Episode Description What if you could screen billions of potential therapies—virtually—in the time it takes to brew your morning coffee? In this episode of scientifica sessions, host Tabari Baker sits down with Tom Neyarapally, CEO and co-founder of Archetype Therapeutics, to explore how AI-native biotech is redefining what's possible in early-stage drug discovery. With a background that spans law, business, and executive leadership at companies like Sema4, Tom offers a rare vantage point on how data, machine learning, and strategic insight converge to accelerate breakthroughs in oncology and beyond. Tom breaks down the science behind generative chemogenomics, a novel platform that Archetype uses to computationally model and prioritize billions of molecules against real-world patient data. He shares how this approach is opening new doors for underserved populations—starting with patients facing non-small cell lung cancer—and gives an insider's look at the challenges of validating AI-driven assets in a tightly regulated environment. From AI-driven virtual screens to pragmatic lessons on leading AI-first biotech startups, this episode is a masterclass for executives navigating the future of translational science. If you're in biotech, pharma, or diagnostics—and responsible for building what's next—this conversation will leave you rethinking how you approach discovery, evidence, and leadership. What We Covered Understanding Generative Chemogenomics Explaining generative chemogenomics in accessible terms and how it differs from traditional drug discovery methods The role of clinicogenomic data integration in enhancing virtual screening predictive power How regulatory and payer stakeholders are responding to generative AI outputs as evidence in early development Sharper Early-Stage Discovery in Practice Deep dive into Archetype's recent lung cancer program and how virtual screening translates to actionable candidate molecules Validation strategies for AI-generated molecules before advancing to in vitro or animal models Advantages and risks of AI-driven discovery models versus classic high-throughput screening approaches AI Leadership & Strategic Integration Essential capabilities biotech executives need to enable AI integration in drug pipelines Aligning AI outputs with Medical Affairs, Real-World Evidence, and clinical leadership strategies Medical Affairs' evolving role in educating stakeholders about AI-generated therapeutics legitimacy The future landscape of AI-driven R&D and commercialization across pharma Leadership Insights & Founding Journey Leadership lessons from scaling teams at Sema4 and Archetype in high-growth bio-AI environments Practical cultural and organizational advice for senior leaders building AI-first biotech startups Future Roadmap & Vision Next-generation developments in generative chemogenomics Strategic outlook for AI-native drug discovery becoming industry standard Guest Bio Tom Neyarapally is the CEO and Co-Founder of Archetype Therapeutics, an AI-native company pioneering the use of generative chemogenomics in patient data-driven drug R&D in cancer and other diseases. Previously, Tom was CCO and founding team member at Sema4, a patient-centered health intelligence and genetic testing company that went public in 2021. He was also a member of the founding team and EVP, Corporate Development at the causal AI drug discovery company Aitia. After graduate school, Tom served as a corporate and IP lawyer at Chadbourne Parke LLP and Frommer Lawrence & Haug LLP. He started his career after college as an analyst focused on pharmaceuticals at the management consulting firm Arthur D. Little. Tom earned a B.S. in chemical engineering (Honors Scholar/cum laude) from the University of Connecticut and a J.D. and M.B.A. from Cornell University. His unique combination of technical, legal, and business expertise provides him with a distinctive perspective on navigating the intersection of AI innovation and pharmaceutical development in highly regulated environments. Connect with Tom: Website: Email: LinkedIn: If this conversation sparked new ideas or made you rethink how you align discovery with downstream strategy, subscribe to scientifica sessions. We bring you the leaders shaping what's next in biotech, medtech, and pharma. Connect with us at . Episode recorded on July 25, 2025. scientifica sessions is produced by kronos scientifica, exploring the intersection of innovation, evidence, and strategy in life sciences. At scientifica sessions, we love our music! Here's are the original tracks used: Opening - scientifica sessions Theme 00:07:28 - Drift 00:19:44 - Breathe 00:45:54 - The Turning Closing - scientifica sessions Theme Like what you heard? Check out our producers, .
/episode/index/show/4bf1c28b-29db-4d52-81c6-5158929c0248/id/38049225